文献速递胸部肿瘤放疗放疗物理与技术

肺癌SABR中MLC追踪减少PTV体积并保护危及器官

MLC tracking for lung SABR reduces planning target volumes and dose to organs at risk.
PubMed 文献 · Radiother Oncol · 2017-06-24

本研究对10例曾接受基于ITV计划治疗的肺癌SABR患者,重新制定MLC追踪与midV计划,并在运动模体上模拟真实肺运动实施照射,于计划扫描中重建递送剂量。结果显示MLC追踪和midV较ITV计划PTV体积平均减少33.9%和22%,MLC追踪的GTV覆盖更优且危及器官剂量降低更多。

要点

  • MLC追踪与midV计划较ITV计划分别平均减少PTV体积33.9%和22%。
  • MLC追踪的GTV剂量覆盖优于midV和ITV计划。
  • MLC追踪降低肺、食管、大血管、气管、心脏和脊髓的剂量。

核心结论

  • MLC追踪较midV和ITV计划减少PTV体积、改善GTV剂量覆盖并更好地保护危及器官。

研究设计与样本

  • 对10例原接受ITV计划治疗的肺癌SABR患者重新制定MLC追踪与midV计划。
  • 所有计划在直线加速器上对运动模体以真实肺运动模拟治疗实施,并在患者计划扫描中重建递送剂量。

主要发现

  • MLC追踪与midV计划较ITV计划平均减少PTV体积分别为33.9%和22%。
  • MLC追踪的GTV剂量覆盖优于midV和ITV计划。
  • MLC追踪较ITV计划降低肺平均剂量0.8Gy、食管D3cc 1.9Gy、大血管D10cc 3.2Gy、气管D4cc 1.1Gy、心脏D1cc 2.0Gy、脊髓D0.03cc 0.5Gy。
  • midV较ITV计划降低肺平均剂量0.2Gy、食管D3cc 1.4Gy、大血管D10cc 1.3Gy、气管D4cc 0.9Gy、心脏D1cc 0.5Gy,脊髓D0.03cc增加0.1Gy。

临床怎么用

  • 肺癌SABR可采用MLC追踪以缩小PTV体积并降低危及器官剂量。

局限性

  • 研究基于10例患者计划在运动模体上的模拟实施与剂量重建,非临床患者实际治疗验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Assess the dosimetric impact of multi-leaf collimator (MLC) tracking and mid-ventilation (midV) planning compared with the internal target volume (ITV)-based planning approach for lung Stereotactic Ablative Body Radiotherapy (SABR). METHOD: Ten lung SABR patients originally treated with an ITV-based plan were re-planned according to MLC tracking and midV planning schemes. All plans were delivered on a linac to a motion phantom in a simulated treatment with real lung motions. Delivered dose was reconstructed in patient planning scans. ITV-based, tracking and midV regimes were compared at the planning and delivered stages based on PTV volume and dose metrics for the GTV and OAR. RESULTS: MLC tracking and midV schemes yielded favourable outcomes compared with ITV-based plans. Average reduction in PTV volume was (MLC tracking/MidV) 33.9%/22%. GTV dose coverage performed better with MLC tracking than the other regimes. Reduction in dose to OAR were for the lung (mean lung dose, 0.8Gy/0.2Gy), oesophagus (D3cc, 1.9Gy/1.4Gy), great vessels (D10cc, 3.2Gy/1.3Gy), trachea (D4cc, 1.1Gy/0.9Gy), heart (D1cc, 2.0Gy/0.5Gy) and spinal cord (D0.03cc, 0.5Gy/-0.1Gy). CONCLUSION: MLC tracking showed reduction in PTV volume, superior GTV dose coverage and organ dose sparing than MidV and ITV-based strategies.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Caillet V, Keall PJ, Colvill E, et al. MLC tracking for lung SABR reduces planning target volumes and dose to organs at risk. Radiother Oncol. 2017. PMID: 28655454. doi:10.1016/j.radonc.2017.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。